Markets
Deutsche Bank analyst Liam Fitzpatrick maintained a Buy rating on Anglo American (AAUKF – Research Report) on April 22 and set a price target of p3600.00. The company’s shares closed last Friday at $43.87, close to its 52-week high of $44.28.
Fitzpatrick has an average return of 35.9% when recommending Anglo American.
According to TipRanks.com, Fitzpatrick is ranked #2927 out of 7474 analysts.
Anglo American has an analyst consensus of Moderate Buy, with a price target consensus of $44.24, a 0.8% upside from current levels. In a report issued on April 8, Berenberg Bank also maintained a Buy rating on the stock with a p3900.00 price target.
Sherwin-Williams Company (SHW) Receives a Buy from Evercore ISI
Evercore ISI analyst Greg Melich maintained a Buy rating on Sherwin-Williams Company (SHW – Research Report) on April 23. The company’s shares closed last Friday at $273.92, close to its 52-week high of $274.44.
According to TipRanks.com, Melich is a 3-star analyst with an average return of 9.8% and a 62.9% success rate. Melich covers the Consumer Goods sector, focusing on stocks such as Floor & Decor Holdings, Advance Auto Parts, and Walmart.
Currently, the analyst consensus on Sherwin-Williams Company is a Moderate Buy with an average price target of $270.98, a 0.0% downside from current levels. In a report issued on April 21, RBC Capital also maintained a Buy rating on the stock with a $269.00 price target.
Markets
BTIG analyst Thomas Shrader maintained a Hold rating on Biogen (BIIB – Research Report) on April 22. The company’s shares closed last Friday at $262.63.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of 18.6% and a 41.2% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Stoke Therapeutics, and Gain Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $304.24 average price target, which is a 16.9% upside from current levels. In a report issued on April 8, RBC Capital also maintained a Hold rating on the stock with a $263.00 price target.
Markets
Leerink Partners analyst Geoff Porges maintained a Hold rating on Radius Health (RDUS – Research Report) on April 22. The company’s shares closed last Friday at $20.90.
According to TipRanks.com, Porges is a 3-star analyst with an average return of 5.9% and a 49.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Theravance Biopharma.
Radius Health has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.
Radius Health’s market cap is currently $980.1M and has a P/E ratio of -8.50. The company has a Price to Book ratio of -7.25.
Genuine Parts Company (GPC) Gets a Hold Rating from Evercore ISI Evercore ISI analyst Greg Melich maintained a Hold rating on Genuine Parts Company (GPC – Research Report) on April 23. The company’s shares closed last Friday at $122.33, close to its 52-week high of $123.22.
According to TipRanks.com, Melich is a 3-star analyst with an average return of 9.8% and a 62.9% success rate. Melich covers the Consumer Goods sector, focusing on stocks such as Floor & Decor Holdings, Advance Auto Parts, and Walmart.
Currently, the analyst consensus on Genuine Parts Company is a Moderate Sell with an average price target of $111.67, a -7.5% downside from current levels. In a report issued on April 20, RBC Capital also maintained a Hold rating on the stock with a $115.00 price target.